Back to matchesWe found a matchYour institution may have access to this item. Find your institution then sign in to continue.TitleLetter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients.AuthorsFiorino, G.; Correale, C.; Radice, S.; Allocca, M.; Furfaro, F.; Gilardi, D.; Nagore, D.; Del Rio, L.; Pascual, J.; Martínez, A.; Danese, S.AbstractThis article is linked to Komaki et al papers. To view these articles visit https://doi.org/10.1111/apt.14274 and https://doi.org/10.1111/apt.13990.SubjectsINFLIXIMAB; INFLAMMATORY bowel disease treatment; ULCERATIVE colitis; INFLAMMATORY bowel diseases; CROHN'S diseasePublicationAlimentary Pharmacology & Therapeutics, 2017, Vol 46, Issue 9, p903ISSN0269-2813Publication typeArticleDOI10.1111/apt.14262